Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods – 8 September 2023

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the provision of therapeutic goods in Australia, ensuring their quality, safety, and efficacy. The Act was introduced to address the need for a cohesive legislative framework governing the approval, registration, manufacturing, and advertising of therapeutic goods. The Therapeutic Goods Administration, under the Department of Health and Aged Care, is responsible for the enactment and administration of this legislation. The overarching policy objective of the Act is to protect public health by ensuring that therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy. This includes the regulation of manufacturing processes through the issuance of licences to entities that meet the necessary standards, as evidenced by the recent grant of a licence to Neptune Bio-Innovations Pty Ltd, ensuring their compliance with the stringent requirements set forth by the Therapeutic Goods Administration.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods within Australia, encompassing a wide range of products including medicines, medical devices, and blood products. The Act applies to entities such as manufacturers, importers, and suppliers of therapeutic goods, ensuring they meet specific standards for safety, quality, and efficacy. This legislation extends across the Commonwealth of Australia, applying uniformly to all states and territories. The Act mandates that manufacturers obtain a licence to produce therapeutic goods, as evidenced by the recent notification concerning the grant of a manufacturing licence to Neptune Bio-Innovations Pty Ltd. This licence signifies compliance with the rigorous standards set by the Therapeutic Goods Administration, ensuring the products are safe for public use. The Act also includes provisions for subordinate instruments, which may further detail the specific requirements and conditions for different classes of therapeutic goods, thereby extending or restricting the application of the primary Act.

Key Provisions

The Therapeutic Goods Act 1989, under Section 38, outlines the process for granting a licence to entities such as NEPTUNE BIO-INNOVATIONS PTY LTD to manufacture therapeutic goods. In this instance, the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration, has issued a written notice to grant Licence No. MI-2019-LI-10934-1 to NEPTUNE BIO-INNOVATIONS PTY LTD. The licence allows the company to manufacture therapeutic goods at their specified premises, Unit E4, 3-29 Birnie Avenue, Lidcombe, NSW, 2141. The publication of this licence serves as a formal announcement of the approval granted to the company to carry out manufacturing activities under the conditions stipulated by the Act. Entities granted a licence under the Therapeutic Goods Act 1989 are subject to various obligations and requirements to ensure compliance with manufacturing standards and regulations. These obligations include adhering to good manufacturing practices, maintaining proper records of the manufacturing processes, and ensuring that the therapeutic goods produced meet the quality and safety standards set by the Therapeutic Goods Administration. The licence holder must also conduct regular inspections and audits to verify compliance with these standards and promptly report any deviations or issues that arise during the manufacturing process. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in severe consequences, both civil and criminal. For instance, if a licence holder fails to adhere to the stipulated manufacturing practices or quality standards, the Therapeutic Goods Administration may take enforcement actions. This could include the suspension or revocation of the licence, which would halt the manufacturing operations of the entity. Furthermore, the Act provides for penalties such as fines and imprisonment for serious breaches, with the maximum penalties varying depending on the severity and nature of the offence. For example, individuals or entities found guilty of manufacturing therapeutic goods that are unsafe or of substandard quality may face significant fines and imprisonment terms as outlined in the Act. These stringent measures are in place to ensure that the therapeutic goods supplied to the Australian market are safe, effective, and of high quality.